LivaNova wins FDA PMA for aura6000 sleep apnea implant

LivaNova said the US Food and Drug Administration granted premarket approval for its aura6000 system, an implantable hypoglossal nerve stimulation device for adults with moderate to severe obstructive sleep apnea who have failed, can’t tolerate, or aren’t eligible for standard therapies such as PAP, oral appliances, or pharmacotherapy. FDA’s PMA database shows the decision was made on March 18, 2026, and the approved indication covers patients with an apnea-hypopnea index of 15 to 65. The company is also highlighting a differentiator: aura6000 is the first FDA-approved hypoglossal nerve stimulation therapy in the US without contraindication or warning language tied to complete concentric collapse, and without a pre-implant drug-induced sleep endoscopy requirement in its labeling. (accessdata.fda.gov)

Why it matters: For veterinary professionals, this is primarily a medical device regulation story rather than a companion animal care development, but it’s still useful context on how FDA evaluates implantable neuromodulation platforms, pivotal trial evidence, and post-approval commitments. The approval was supported by the OSPREY randomized trial, which met its primary safety and efficacy endpoints at 6 months versus control and enrolled adults with moderate to severe OSA without excluding patients at risk for complete concentric collapse. LivaNova previously reported 12-month top-line data showing a 65% active responder rate, defined as at least a 50% AHI reduction with AHI below 20, along with median 68% reductions in both apnea-hypopnea index and oxygen desaturation index; the company also reported improved patient-reported sleep disturbance outcomes and a 69% rate of at least 25% ODI reduction at month 7 versus 38% in controls. FDA has also listed a post-approval follow-up study for the device, underscoring that PMA is approval with ongoing evidence obligations, not the end of regulatory scrutiny. (clinicaltrials.gov)

What to watch: LivaNova says its next-generation, MRI-compatible version is expected to launch in the first half of 2027, pending FDA supplement review, and the company has said that version is being designed with secure remote configuration and a rechargeable battery. Commercialization timing and payer uptake will be the next key markers. (nasdaq.com)